• Revenue from operations up 20.3% to $8.4m
• EBITDA improved to -$436k (PCP: -$2.7m)
• Operating expenses reduced $1.1M (14.2%)

IDT Australia Limited (ASX: IDT) reports a encouraging improvement in underlying operating performance for the half-year ended 31 December 2025 (H1FY26), underpinned by its strategic realignment strategy under new leadership. Ordinary revenue from IDT's three core verticals increased 20.3% on the previous corresponding period (PCP) to $8.4 million, while earnings before interest, tax, depreciation and amortisation (EBITDA) improved by $2.3 million over the PCP to a modest loss of $436k. The decline in expenses demonstrates IDT's strong cost discipline, better reallocation of resources and investments in automation. As a result, annualised savings are now forecast to reach $2 million compared to the Company's initial forecast of ~$1 million. The API Manufacturing business unit was the standout performer with interim revenue jumping 191.4% PCP to $3 million. The Specialty Orals business increased by 25.8% PCP to $2.5 million, while the Sterile Fill (Advanced Therapies) business recorded a 25.7% PCP drop in interim revenue to $2.9 million due to the timing of customer projects. The Board and new executive team have acted decisively to correct the recent trajectory and reposition the business for sustainable performance, including sharpening commercial focus, reallocating resources, and pursuing cost savings from digitisation and automation.

IDT enters the second half of FY26 with a solid pipeline across its three business verticals and a more focused commercial strategy. The Company remains committed to delivering a positive operating profit in the near-term, increasing productivity, expanding its customer base, and progressing strategic initiatives that support longer-term growth.